Enhancement of the immunogenicity of an alphavirus replicon-based DNA vaccine against classical swine fever by electroporation and coinjection with a plasmid expressing porcine interleukin 2

Vaccine

Volumn 30, Issue 24, 2012, Pages 3587-3594

  Tian, Da Yong ^a   Sun, Yuan ^a   Wai, Sing Fai ^b   Lee, Fuk Ki ^b   Meng, Qi Lin ^a   Suen, Kar Man ^b   Wang, Nan ^a   Han, Wen ^a   Li, Su ^a   Li, Yong Feng ^a   Li, Dan ^a   Ling, Li Jun ^a   Liao, Ya Jin ^a   Qiu, Hua Ji ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b GreenPak Biotech Ltd   (China)

Author keywords

Alphavirus replicon; Classical swine fever; Electroporation; Interleukin 2

Indexed keywords

ALPHAVIRUS REPLICON BASED DNA VACCINE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; UNCLASSIFIED DRUG;

ALPHA VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLASSICAL SWINE FEVER; CONTROLLED STUDY; ELECTROPORATION; IMMUNIZATION; IMMUNOGENICITY; LETHALITY; LYMPHOCYTE PROLIFERATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; REPLICON; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ALPHAVIRUS; ANIMALS; ANTIBODIES, VIRAL; CELL PROLIFERATION; CLASSICAL SWINE FEVER; ELECTROPORATION; GENETIC VECTORS; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-4; LYMPHOCYTES; PLASMIDS; SWINE; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 84860991516     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.049     Document Type: Article

References (24)

1. Moennig V., Floegel-Niesmann G., Greiser-Wilke I. Clinical signs and epidemiology of classical swine fever: a review of new knowledge. Vet J 2003, 165(1):11-20.
2. Rice C.M. Flaviviridae: the viruses and their replication. Fundamental virology 1996, 931-959. Lippincott Raven, Philadelphia. third ed. D.M. Knipe, P.M. Howley (Eds.).
3. van Oirschot J.T. Vaccinology of classical swine fever: from lab to field. Vet Microbiol 2003, 96(4):367-384.
4. Li N., Qiu H.J., Zhao J.J., Li Y., Wang M.J., Lu B.W., et al. A Semliki Forest virus replicon vectored DNA vaccine expressing the E2 glycoprotein of classical swine fever virus protects pigs from lethal challenge. Vaccine 2007, 25(15):2907-2912.
5. Tsang C., Babiuk S., van Drunen Littel-van den Hurk S., Babiuk L.A., Griebel P. A single DNA immunization in combination with electroporation prolongs the primary immune response and maintains immune memory for six months. Vaccine 2007, 25(30):5485-5494.
6. Lin Y., Qigai H., Xiaolan Y., Weicheng B., Huanchun C. The co-administrating of recombinant porcine IL-2 could enhance protective immune responses to PRV inactivated vaccine in pigs. Vaccine 2005, 23(35):4436-4441.
7. Toubaji A., Hill S., Terabe M., Qian J., Floyd T., Simpson R.M., et al. The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 2007, 25(31):5882-5891.
8. McGettigan J.P., Koser M.L., McKenna P.M., Smith M.E., Marvin J.M., Eisenlohr L.C., et al. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing IV-1 proteins and IL-2. Virology 2006, 344(2):363-377.
9. Zhao J.J., Cheng D., Li N., Sun Y., Shi Z., Zhu Q.H., et al. Evaluation of a multiplex real-time RT-PCR for quantitative and differential detection of wild-type viruses and C-strain vaccine of classical swine fever. Vet Microbiol 2008, 126(1-3):1-10.
10. Sun Y., Liu D.F., Wang Y.F., Liang B.B., Cheng D., Li N., et al. Generation and efficacy evaluation of a recombinant adenovirus expressing the E2 protein of classical swine fever virus. Res Vet Sci 2010, 88(1):77-82.
11. Buonavoglia C., Falcone E., Pestalozza S., Di Trani L., D'Amore E. A rapid serum neutralization test in microplates for the detection of antibodies to hog cholera virus. J Virol Methods 1989, 23(1):77-79.
12. Peng W.P., Hou Q., Xia Z.H., Chen D., Li N., Sun Y., et al. Identification of a conserved linear B-cell epitope at the N-terminus of the E2 glycoprotein of Classical swine fever virus by phage-displayed random peptide library. Virus Res 2008, 135(2):267-272.
13. Miyamoto T., Min W., Lillehoj H.S. Lymphocyte proliferation response during Eimeria tenella infection assessed by new, reliable nonradioactive colorimetric assay. Avian Dis 2002, 46(1):10-16.
14. Sardesai N.Y., Weiner D.B. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011, 23(3):421-429.
15. Liu M.A., Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 2005, 55:25-40.
16. Prud'homme G.J., Draghia-Akli R., Wang Q. Plasmid-based gene therapy of diabetes mellitus. Gene Ther 2007, 14(7):553-564.
17. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007, 81(10):5257-5269.
18. Siegel J.P., Sharon M., Smith P.L., Leonard W.J. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science 1987, 238(4823):75-78.
19. Zhang X., Divangahi M., Ngai P., Santosuosso M., Millar J., Zganiacz A., et al. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine 2007, 25(7):1342-1352.
20. Anderson M.S., Venanzi E.S., Klein L., Chen Z., Berzins S.P., Turley S.J., et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002, 298(5597):1395-1401.
21. Collins R.A., Oldham G. Recombinant human interleukin 2 induces proliferation and immunoglobulin secretion by bovine B-cells: tissue differences and preferential enhancement of immunoglobulin A. Vet Immunol Immunopathol 1993, 36(1):31-34.
22. Cai H., Yu D.H., Tian X., Zhu Y.X. Coadministration of interleukin 2 plasmid DNA with combined DNA vaccines significantly enhances the protective efficacy against Mycobacterium tuberculosis. DNA Cell Biol 2005, 24(10):605-613.
23. Huang X., Ye D., Thorpe P.E. Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine. Vaccine 2011, 29(29-30):4785-4793.
24. Nunberg J.H., Doyle M.V., York S.M., York C.J. Interleukin-2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc Natl Acad Sci USA 1989, 86(11):4240-4243.